剂量密集化疗治疗晚期上皮性卵巢癌疗效观察

目的：探讨剂量密集化疗和标准化疗方案治疗晚期上皮性卵巢癌的临床疗效。方法：选取天津市第五中心医院院内化疗的晚期上皮性卵巢癌患者共89例，将患者随机分为剂量密集组45例和标准方案组44例，2组患者的年龄、病理分型和肿瘤临床分期差异均无统计学意义（P＞0.05）。标准方案组：紫杉醇180 mg/m2（静脉滴注维持3 h），随后使用卡铂AUC 6（静脉滴注维持1 h，第1天），间隔3周，共6个疗程。剂量密集组：紫杉醇80 mg/m2第1，8，15天+卡铂AUC 6（静脉滴注维持1 h，第1天），每周期间隔3周，共6个疗程。2组进行治疗并随访3年，分别对2组患者的近期疗效、远期疗效和不良反应等进行比较。结果：剂量密集组总体缓解率高于标准方案组，差异有统计学意义（P＜0.05）；疾病无进展生存期（PFS）和3年生存率指标的比较，剂量密集组显著高于标准方案组（P＜0.01）；虽然其不良反应发生率亦高于标准方案组，但仅Ⅲ～Ⅳ级贫血发生率2组相比差异有统计学意义（P＜0.05），其余发生率差异无统计学意义（P＞0.05）。结论：剂量密集化疗可有效提高晚期上皮性卵巢癌患者的3年生存率，延缓肿瘤复发。

Clinical Observation of Dose-dense Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer

Objective：To investigate the clinical efficacy of dose-dense chemotherapy and standard chemotherapy regimen in the treatment of advanced epithelial ovarian cancer. Methods：Select 89 patients who were diagnosed by pathology with advanced epithelial ovarian cancer in The Fifth Central Hospital of Tianjin. The patients were randomly divided into dose dense group of 45 cases and a standard regimen in 44 cases，the age，pathological type and clinical stage of the two groups patients were not statistically significant （P＞0.05）. Standard solutions group：Paclitaxel 180 mg/m2（intravenous drip for 3 h），then the use of carboplatin AUC 6（intravenous drip for 1 h，the first day），the interval of 3 weeks，a total of 6 courses. Dose dense group：Paclitaxel 80 mg/m2 1，8，15 days + carboplatin AUC 6（intravenous drip for 1 h，the first day），during the interval of 3 weeks，a total of 6 courses. The two groups were treated and followed up for 3 years，compared the two groups of patients with long-term efficacy，therapeutic effect and adverse reaction. Results：The total remission rate of dose dense group was higher than that of the standard regimen group，the difference was statistically significant（P＜0.05）. Comparison of progression free survival and 3 year survival rate，the dose dense group was significantly higher than that of standard solutions group （P＜0.01）. Although the incidence of the adverse reaction rate was also higher than that of the standard regimen group，there was statistically significant but only Ⅲ～Ⅳ anemia incidence rate difference between the two groups （P＜0.05），the rest incidences were no significant difference（P＞0.05）. Conclusions：The dose dense chemotherapy can effectively improve the 3 year survival rate of advanced epithelial ovarian cancer patients，delaying tumor recurrence.